EASTERN COOPERATIVE ONCOLOGY GROUP

Project: Research project

Description

The primary goals of the research proposed are to improve medical care,
prolong patient survival with optimal achievement in quality of life, and
rapidly assimilate data from clinical trials performed within the
framework of the efforts of the Eastern Cooperative Oncology Group. Our
approach to patient care is enhanced by extensive and organized
involvement in additional disciplines; such cooperation is designed to
provide patients with neoplastic disease the most promising therapy
available. Although we are new members to the Eastern Group, our
ultimate contribution can best be anticipated by reflecting on our past
record in the Southeastern Cancer Study Group: Indiana University led
the SECSG in the accrual of patients on multimodality protocols, and our
leadership role was further defined by our achieving the highest patient
accession rate within the group for its last two funded years and the
exceptional administrative and participatory involvement in committee and
protocol responsibilities by our faculty. Our 1987 patient accession total is not reflective of our future accrual
rate with ECOG. Of necessity, we are competing scientifically important
studies which were begun during our tenure with the SECSG. Of particular
note are the extensive small cell lung cancer study (LUN 302) and our
investigation of standard versus double dose chemotherapy for testis
cancer (GU 303). Both protocols have strong accrual, 94 patients in all.
These patient populations will become an additional resource for ECOG
studies when LUN 302 and GU 303 have been completed, no later than May
1989. Yet another patient population will become available when our
Veterans Administration Hospital completes its Institutional Assurance
with the OPRR. Support for both ongoing and new research conducted by Indiana University
will enable us to expand our leadership responsibilities within the
Eastern Cooperative Oncology Group.
StatusFinished
Effective start/end date5/1/894/30/16

Funding

  • National Institutes of Health: $258,301.00
  • National Institutes of Health
  • National Institutes of Health: $261,237.00
  • National Institutes of Health: $299,793.00
  • National Institutes of Health: $324,627.00
  • National Institutes of Health: $134,607.00
  • National Institutes of Health: $266,049.00
  • National Institutes of Health
  • National Institutes of Health: $324,626.00
  • National Institutes of Health: $285,722.00
  • National Institutes of Health
  • National Institutes of Health: $251,883.00
  • National Institutes of Health: $259,060.00
  • National Institutes of Health: $210,390.00
  • National Institutes of Health: $243,839.00
  • National Institutes of Health: $278,182.00
  • National Institutes of Health: $268,117.00
  • National Institutes of Health
  • National Institutes of Health: $209,678.00
  • National Institutes of Health
  • National Institutes of Health: $284,992.00
  • National Institutes of Health: $281,735.00
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health: $330,145.00
  • National Institutes of Health: $294,857.00

Fingerprint

Organized Financing
Testicular Neoplasms
Research Personnel
Research
Breast
Clinical Trials
Vulnerable Populations
Leukemia
Breast Neoplasms
Population
Paclitaxel
County Hospitals
gallium nitrate
Nursing
Urinary Bladder Neoplasms
Thymoma
Ifosfamide
Neoplasms
gemcitabine
Amish

ASJC

  • Medicine(all)